Showing 771-780 of 1539 results for "".
- Benzac Acne Solutions Premieres “Insta-Dramedy” Webserieshttps://practicaldermatology.com/news/benzac-acne-solutions-premieres-insta-dramedy-webseries/2458955/Galderma Laboratories, L.P launched its first webisode series, “The Benzacs,” a teen insta-dramedy told through 15-second Instagram videos and more than 80 images and short videos. The webseries features the new over-the-counter (OTC) acne treatment Benzac® Acne Solutions, which c
- NanoViricides: Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Modelhttps://practicaldermatology.com/news/nanoviricides-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model/2458963/NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the la
- RXi Pharmaceuticals Receives FDA Orphan Drug Designation for Samcyprone for Melanomahttps://practicaldermatology.com/news/rxi-pharmaceuticals-receives-fda-orphan-drug-designation-for-samcyprone-for-melanoma/2458964/The FDA granted RXi Pharmaceuticals Corporation Orphan Drug Designation of its second clinical candidate, Samcyprone™, for the treatment of malignant melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone™ is bei
- Dermira Presents Clinical Data for DRM01 Acne Programhttps://practicaldermatology.com/news/dermira-presents-clinical-data-for-drm01-acne-program/2458981/Dermira, Inc. presented clinical data from its DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne
- Novel Anti-Biofilm AQUACEL™ Ag+ Dressing Demonstrates Positive Results in Hard-to-Heal Woundshttps://practicaldermatology.com/news/novel-anti-biofilm-aquacel-ag-dressing-demonstrates-positive-results-in-hard-to-heal-wounds/2458998/A new, multi-country, clinical evaluation study showed that AQUACEL™ Ag+ wound dressing demonstrated positive results in wounds, including those compromised by biofilm and/or infection. AQUACEL™ Ag+ dressings are designed to disrupt biofilm and kill infection-
- Pfizer Announces FDA Acceptance For Review of Supplemental New Drug Application for Oral Xeljanz For Plaque Psoriasishttps://practicaldermatology.com/news/pfizer-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-oral-xeljanz-for-plaque-psoriasis/2459011/The FDA accepted for review Pfizer Inc.’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) 5mg and 10mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to sever
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- FDA Accepts Investigational New Drug Application for Alphaeon's Neurotoxin Evosyalhttps://practicaldermatology.com/news/20140909-fda_accepts_investigational_new_drug_application_for_alphaeons_neurotoxin_evosyal/2459123/The FDA accepted the Investigational New Drug (IND) Application to conduct clinical studies for EVOSYAL, an botulinum toxin Type A neurotoxin that was acquired by Alphaeon last year as part of the acquisition of Evolus Inc. “The product development team
- Novan's Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model: Presentationhttps://practicaldermatology.com/news/20140909-novans_nitric_oxide_drug_candidate_inhibits_growth_of_papillomavirus_in_translational_animal_model_presentation/2459124/Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced that Novan's nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. About two-thirds of healthy American adults are infected with human papillom
- KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Applicationhttps://practicaldermatology.com/news/20140711-kythera_biopharmaceuticals_announces_fda_acceptance_of_atx-101_new_drug_application/2459173/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficien